Recent laboratory findings have indicated that the proton-pump inhibitor (PPI) lansoprazole is highly active against Mycobacterium tuberculosis, but there has been no clinical research into this effect.
In a paper in PLoS Medicine (21 November 2017), researchers used data from the UK Clinical Practice Research Datalink to compare the incidence of tuberculosis in people taking lansoprazole with that among those taking omeprazole or pantoprazole, two PPIs that have no known activity against M. tuberculosis[1].
Read more: http://bit.ly/2nb3L88